Cellular responses to EGFR inhibitors and their relevance to cancer therapy. - Wikidata - awgldk - TriplyDB

Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

http://www.wikidata.org/entity/Q36003118

about

PI3K/AKT/mTOR Pathway in Angiogenesis Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Monitoring the cytoskeletal EGF response in live gastric carcinoma cells Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy Cytohesins/ARNO: the function in colorectal cancer cells Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer Amorphous Silica Particles Relevant in Food Industry Influence Cellular Growth and Associated Signaling Pathways in Human Gastric Carcinoma Cells EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation.Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.Confocal laser endomicroscopy and immunoendoscopy for real-time assessment of vascularization in gastrointestinal malignancies.Cembrene Diterpenoids with Ether Linkages from Sarcophyton ehrenbergi: An Anti-Proliferation and Molecular-Docking Assessment.Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase.HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia.Specific antibody-receptor interactions trigger InlAB-independent uptake of Listeria monocytogenes into tumor cell lines.[Translational research in head and neck cancer. Biological characteristics and general aspects].A molecular prognostic model predicts esophageal squamous cell carcinoma prognosis.Identification of new peptide ligands for epidermal growth factor receptor using phage display and computationally modeling their mode of binding.Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization.Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR / SphK1 crosstalk A pharmacogenomic method for individualized prediction of drug sensitivity Apoptosis-inducing effects of cetuximab combined with radiotherapy and hypothermia on human nasopharyngeal carcinoma CNE cells Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4.Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations.Heterogeneity of KRAS Mutation Status in Rectal Cancer Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776.Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.Expression of Eag1 K+ channel and ErbBs in human pituitary adenomas: cytoskeleton arrangement patterns in cultured cells Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review)Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma.Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.Modulating the tumor microenvironment to increase radiation responsiveness.The tumor microenvironment in non-small-cell lung cancer Angiogenesis-related molecular targets in esophageal cancer.

P2860

Q21129332-9E9EFABB-E860-44C0-8744-028A6B21AF20 Q21133610-A00E99CF-3693-4B98-8AB6-EDC335AA9BB3 Q26779221-66308BA1-2ED2-46EB-B488-D3D99B796AA1 Q27318370-1C637409-501D-46DC-AB47-4516BC4668E1 Q28475894-C66965FB-5729-4771-A8A6-26A3F2E49663 Q28540770-A3DD9C8B-DE5C-48FB-B5C6-16AF089E88AF Q28550689-807499D2-9446-4F19-A1B7-66A836980C1F Q29249068-5ABEFEAF-AE98-4BDF-B954-3F86C4B71569 Q33667547-BF636874-AB88-4C2B-9A8C-51D6460C248E Q33779199-E5DCE27A-402E-4FD9-836B-EAE4D00AC44B Q33789194-330BBB43-756A-4E29-B584-C660931EA264 Q33833452-023E3848-4ED8-4296-B3F5-5F3D3D74D62F Q33918829-159A6D28-F6DE-482E-AA3A-9C526435FD7F Q33947789-4208369E-3672-4A9A-8BF8-1D3B3EF4611F Q33957227-83D822B6-1F68-4584-B167-B5C46A5760AF Q34000961-0F3CEE88-23AD-48EE-8B97-A4F60EAF0C81 Q34084021-55991B40-C84E-4914-9CB4-D4FFB8C8DA32 Q34089704-718ECD45-084A-44E2-BD83-E800D2C1226F Q34138796-9F50C00E-AA1A-49CC-80E1-5DEEBADA8DE2 Q34654728-FE5AEDA0-153A-42B5-8CBB-F4A0E7614D30 Q35176386-B9B5BA81-708D-4533-B126-19704828C859 Q35480110-21CF6EB1-2A4E-42E3-90B0-D81278EDB69E Q35553145-78F694C1-6C94-42E7-AF7A-B0A5083E33FF Q35642677-7C663FB2-8AFE-4F9B-B398-08DF6BB37382 Q35985611-9D69AFFB-C366-4A3B-B930-664A0193A778 Q36225686-2714446D-4428-4F09-990F-82F4BAE03B59 Q36371890-EDFB0BDE-0B4C-4673-B88E-B2744195CB4E Q36584340-EBE78F9A-3424-4B7F-821F-0ADF01D8FD95 Q36635273-109FE647-D0AC-4AC9-9BF3-902F7D5BA3EB Q36813117-C4DD59B8-244E-4065-879A-966BC5B86A13 Q36935966-7729BC76-E656-4D88-9771-926C0D7B5CE2 Q37158137-96C25161-5EB4-4DEC-B2B5-EC9EFD1F5BF5 Q37200453-826F9AEC-7A77-4EBC-95F8-1F8EB1716DF3 Q37260992-A958CBE9-A765-4CEF-9DF8-1B5588458C45 Q37277197-1F65C8B2-727C-41CC-803A-09A99F5119C0 Q37299934-DA0D1FFD-DB84-4A1A-ADAE-D5CC078ED2B4 Q37329842-E90D3DD0-FCD7-4E0D-983E-29F48D448115 Q37613364-312D443D-CFB1-44A8-9C46-6E786798537A Q37777872-DDB02A6E-BBAD-470F-8500-B75BBA7B53D5 Q37858534-C08EA099-836D-4C3A-9F4B-0EADF3954A7B

P2860

Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

http://www.wikidata.org/entity/Q36003118

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

@ast

Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

@en

type

label

Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

@ast

Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

@en

prefLabel

Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

@ast

Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

@en

P1433

Q36003118-1EA405EC-D85F-4163-8445-C139BB499D6C

P1476

Q36003118-D5422A7A-A174-49EA-82A0-5324FAD7F4FB

P2093

Q36003118-249B65CD-B4B2-4E52-AB97-6C8E2D5D37AB

Q36003118-96B1F334-7826-4D23-970B-DCF5225BC64E

P2860

Q36003118-064EBECF-5C7C-4DE4-A589-084B532F90A7

Q36003118-08DAB7AD-8860-4367-9CE0-0F0ADFD0DC8E

Q36003118-09EF3A68-564F-4D8C-B582-CB47A1AB3125

Q36003118-0CCDFC62-17F6-4592-83A9-29AD5428218E

Q36003118-0E3E2D9E-6919-4A7B-8DB4-16D8E59EEDE5

Q36003118-12BF0720-471B-4E90-A2F5-F301B6D013B4

Q36003118-16772FF0-5776-4736-9961-FB8D3DDD87B3

Q36003118-1A488D71-970E-4E66-962F-98AD19879E1C

Q36003118-1B638004-9322-4517-B8AD-5D3EC872915C

Q36003118-1DDCEAB1-7D3B-42C7-9AF3-54CEFFB55332

P304

Q36003118-193614C2-B5A2-4972-BED4-404C12184C8E

P31

Q36003118-F12C79E0-B906-4DB2-8D35-E1DC447C851A

P356

Q36003118-8E92B90E-E170-4722-B212-C975B8DE3512

P407

Q36003118-43DB08C0-FF8A-4E0A-965F-962FA88E9D5C

P433

Q36003118-6A21F2F9-2D49-47CB-9A31-CA8988C3767B

P478

Q36003118-F7BB13FB-3097-4B69-B496-43BCA0737C2F

P577

Q36003118-DC023031-A6B5-41A2-B177-1A75CC12E0B9

P5875

Q36003118-5399B0E6-CE90-4C53-9627-AFFDC94A091B

P698

Q36003118-E682499B-C408-4B92-94A5-5CCCDB1C937D

P932

Q36003118-73CD4BC6-0863-477F-8189-89D6FC010A9D

P356

J.CANLET.2007.02.006

P1433

P1476

Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

@en

P2093

Amit Maity

http://www.w3.org/2001/XMLSchema#string

Pinaki R Dutta

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Protein modules and signalling networks

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Epidermal growth factor induces p11 gene and protein expression and down-regulates calcium ionophore-induced arachidonic acid release in human epithelial cells

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

Epidermal growth factor-related peptides and their receptors in human malignancies

Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth

The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4

P304

165-177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CANLET.2007.02.006

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

254

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6439366

http://www.w3.org/2001/XMLSchema#string

P698

17367921

http://www.w3.org/2001/XMLSchema#string

P932

1986742

http://www.w3.org/2001/XMLSchema#string